Transforming growth factor β1inhibits bone morphogenic protein (BMP)-2 and BMP-7 signaling via upregulation of Ski-related novel protein N (SnoN): Possible mechanism for the failure of BMP therapy?

BMC Medicine

Volumn 10, Issue , 2012, Pages

  Ehnert, Sabrina ^a   Zhao, Jian ^b   Pscherer, Stefan ^c   Freude, Thomas ^a   Dooley, Steven ^d   Kolk, Andreas ^b   Stöckle, Ulrich ^a   Nussler, Andreas K ^a,b   Hube, Robert ^e  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c Klinikum Traunstein   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e OCM Clinic Munich   (Germany)

Author keywords

Alkaline Phosphatase; Mineralized Matrix; Osteoblasts; rhBMPs; TGF

Indexed keywords

ACTIVIN RECEPROR LIKE KINASE 1; BONE MORPHOGENETIC PROTEIN AND ACTIVIN RECEPTOR MEMBRANE BOUND INHIBITOR; HISTONE DEACETYLASE; NOGGIN; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT OSTEOGENIC PROTEIN 1; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; SKI RELATED NOVEL PROTEIN N; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD6 PROTEIN; SMAD8 PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; OSTEOBLAST; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UBIQUITINATION; UPREGULATION; WESTERN BLOTTING;

BLOTTING, WESTERN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 7; CELLS, CULTURED; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENES, REPORTER; HISTONE DEACETYLASES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; OSTEOBLASTS; PROTO-ONCOGENE PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84865812434     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-10-101     Document Type: Article

References (33)

1. Reddi AH. Role of morphogenetic proteins in skeletal tissue engineering and regeneration. Nat Biotechnol 1998, 16:247-252. 10.1038/nbt0398-247, 9528003.
2. Baskin DS, Ryan P, Sonntag V, Westmark R, Widmayer MA. A prospective, randomized, controlled cervical fusion study using recombinant human bone morphogenetic protein-2 with the CORNERSTONE-SR allograft ring and the ATLANTIS anterior cervical plate. Spine (Phila Pa 1976) 2003, 28:1219-1224.
3. Burkus JK, Gornet MF, Schuler TC, Kleeman TJ, Zdeblick TA. Six-year outcomes of anterior lumbar interbody arthrodesis with use of interbody fusion cages and recombinant human bone morphogenetic protein-2. J Bone Joint Surg Am 2009, 91:1181-1189. 10.2106/JBJS.G.01485, 19411467.
4. Geibel PT, Boyd DL, Slabisak V. The use of recombinant human bone morphogenic protein in posterior interbody fusions of the lumbar spine: a clinical series. J Spinal Disord Tech 2009, 22:315-320. 10.1097/BSD.0b013e31817d8161, 19525785.
5. Vaccaro AR, Lawrence JP, Patel T, Katz LD, Anderson DG, Fischgrund JS, Krop J, Fehlings MG, Wong D. The safety and efficacy of OP-1 (rhBMP-7) as a replacement for iliac crest autograft in posterolateral lumbar arthrodesis: a long-term (> 4 years) pivotal study. Spine (Phila Pa 1976) 2008, 33:2850-2862.
6. White AP, Vaccaro AR, Hall JA, Whang PG, Friel BC, McKee MD. Clinical applications of BMP-7/OP-1 in fractures, nonunions and spinal fusion. Int Orthop 2007, 31:735-741. 10.1007/s00264-007-0422-x, 2266670, 17962946.
7. Wu LD, Xiong Y, Yu HC. Effects of rhBMP-2 on cortical strut allograft healing to the femur in revision total hip arthroplasties: an experimental study. Int Orthop 2007, 31:605-611. 10.1007/s00264-006-0235-3, 2266636, 17123081.
8. Leach J, Bittar RG. BMP-7 (OP-1) safety in anterior cervical fusion surgery. J Clin Neurosci 2009, 16:1417-1420. 10.1016/j.jocn.2009.02.012, 19665382.
9. Shimer AL, Oner FC, Vaccaro AR. Spinal reconstruction and bone morphogenetic proteins: open questions. Injury 2009, 40(Suppl 3):S32-38.
10. Koppel H, Riedl E, Braunagel M, Sauerhoefer S, Ehnert S, Godoy P, Sternik P, Dooley S, Yard BA. L-carnosine inhibits high-glucose-mediated matrix accumulation in human mesangial cells by interfering with TGF-{beta} production and signalling. Nephrol Dial Transplant 2011, 26:3852-3858. 10.1093/ndt/gfr324, 21750159.
11. Bonewald LF, Dallas SL. Role of active and latent transforming growth factor beta in bone formation. J Cell Biochem 1994, 55:350-357. 10.1002/jcb.240550312, 7962167.
12. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003, 113:685-700. 10.1016/S0092-8674(03)00432-X, 12809600.
13. Ellies DL, Viviano B, McCarthy J, Rey JP, Itasaki N, Saunders S, Krumlauf R. Bone density ligand, sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J Bone Miner Res 2006, 21:1738-1749. 10.1359/jbmr.060810, 17002572.
14. Ehnert S, Baur J, Schmitt A, Neumaier M, Lucke M, Dooley S, Vester H, Wildemann B, Stockle U, Nussler AK. TGF-beta1 as possible link between loss of bone mineral density and chronic inflammation. PLoS One 2010, 5:e14073. 10.1371/journal.pone.0014073, 2989906, 21124921.
15. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994, 331:1286-1292. 10.1056/NEJM199411103311907, 7935686.
16. Leask A. TGFbeta, cardiac fibroblasts, and the fibrotic response. Cardiovasc Res 2007, 74:207-212. 10.1016/j.cardiores.2006.07.012, 16919613.
17. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193:265-275.
18. Geiser AG, Zeng QQ, Sato M, Helvering LM, Hirano T, Turner CH. Decreased bone mass and bone elasticity in mice lacking the transforming growth factor-beta1 gene. Bone 1998, 23:87-93. 10.1016/S8756-3282(98)00078-7, 9701466.
19. Joyce ME, Roberts AB, Sporn MB, Bolander ME. Transforming growth factor-beta and the initiation of chondrogenesis and osteogenesis in the rat femur. J Cell Biol 1990, 110:2195-2207. 10.1083/jcb.110.6.2195, 2116133, 2351696.
20. Noda M, Camilliere JJ. In vivo stimulation of bone formation by transforming growth factor-beta. Endocrinology 1989, 124:2991-2994. 10.1210/endo-124-6-2991, 2721454.
21. Rosen D, Miller SC, DeLeon E, Thompson AY, Bentz H, Mathews M, Adams S. Systemic administration of recombinant transforming growth factor beta 2 (rTGF-beta 2) stimulates parameters of cancellous bone formation in juvenile and adult rats. Bone 1994, 15:355-359. 10.1016/8756-3282(94)90300-X, 8068458.
22. Erlebacher A, Derynck R. Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype. J Cell Biol 1996, 132:195-210. 10.1083/jcb.132.1.195, 2120709, 8567723.
23. Filvaroff E, Erlebacher A, Ye J, Gitelman SE, Lotz J, Heillman M, Derynck R. Inhibition of TGF-beta receptor signaling in osteoblasts leads to decreased bone remodeling and increased trabecular bone mass. Development 1999, 126:4267-4279.
24. Mohammad KS, Chen CG, Balooch G, Stebbins E, McKenna CR, Davis H, Niewolna M, Peng XH, Nguyen DH, Ionova-Martin SS, Bracey JW, Hogue WR, Wong DH, Ritchie RO, Suva LJ, Derynck R, Guise TA, Alliston T. Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS One 2009, 4:e5275. 10.1371/journal.pone.0005275, 2666804, 19357790.
25. Wang S, Hirschberg R. Bone morphogenetic protein-7 signals opposing transforming growth factor beta in mesangial cells. J Biol Chem 2004, 279:23200-23206. 10.1074/jbc.M311998200, 15047707.
26. Mizuide M, Hara T, Furuya T, Takeda M, Kusanagi K, Inada Y, Mori M, Imamura T, Miyazawa K, Miyazono K. Two short segments of Smad3 are important for specific interaction of Smad3 with c-Ski and SnoN. J Biol Chem 2003, 278:531-536.
27. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001, 10:537-543. 10.1093/hmg/10.5.537, 11181578.
28. Wu XB, Li Y, Schneider A, Yu W, Rajendren G, Iqbal J, Yamamoto M, Alam M, Brunet LJ, Blair HC, Zaidi M, Abe E. Impaired osteoblastic differentiation, reduced bone formation, and severe osteoporosis in noggin-overexpressing mice. J Clin Invest 2003, 112:924-934. 193662, 12975477.
29. Machado MC, Bellodi-Privato M, Kubrusly MS, Molan NA, Tharcisio T, de Oliveira ER, D'Albuquerque LA. Valproic acid inhibits human hepatocellular cancer cells growth in vitro and in vivo. J Exp Ther Oncol 2010, 9:85-92.
30. Ouyang DY, Ji YH, Saltis M, Xu LH, Zhang YT, Zha QB, Cai JY, He XH. Valproic acid synergistically enhances the cytotoxicity of gossypol in DU145 prostate cancer cells: An iTRTAQ-based quantitative proteomic analysis. J Proteomics 2011, 74:2180-2193. 10.1016/j.jprot.2011.06.016, 21726675.
31. Schroeder TM, Westendorf JJ. Histone deacetylase inhibitors promote osteoblast maturation. J Bone Miner Res 2005, 20:2254-2263. 10.1359/JBMR.050813, 16294278.
32. Aksoy A, Sonmez FM, Deger O, Hosver I, Karaguzel G. The effects of antiepileptic drugs on the relationships between leptin levels and bone turnover in prepubertal children with epilepsy. J Pediatr Endocrinol Metab 2011, 24:703-708.
33. Triantafyllou N, Lambrinoudaki I, Armeni E, Evangelopoulos EM, Boufidou F, Antoniou A, Tsivgoulis G. Effect of long-term valproate monotherapy on bone mineral density in adults with epilepsy. J Neurol Sci 2010, 290:131-134. 10.1016/j.jns.2009.12.015, 20056251.